All Outputs (3)

Inhibition of HOX/PBX dimer formation leads to necroptosis in acute myeloid leukemia cells (2017)
Journal Article
Alharbi, R. A., Pandha, H. S., Simpson, G. R., Pettengell, R., Poterlowicz, K., Thompson, A., …Morgan, R. (2017). Inhibition of HOX/PBX dimer formation leads to necroptosis in acute myeloid leukemia cells. Oncotarget, 8(52), https://doi.org/10.18632/oncotarget.20023

The HOX genes encode a family of transcription factors that have key roles in both development and malignancy. Disrupting the interaction between HOX proteins and their binding partner, PBX, has been shown to cause apoptotic cell death in a range of... Read More about Inhibition of HOX/PBX dimer formation leads to necroptosis in acute myeloid leukemia cells.

Integrated analysis of the molecular action of Vorinostat identifies epi-sensitised targets for combination therapy (2017)
Journal Article
Hay, J. F., Lappin, K., Liberante, F., Kettyle, L. M., Matchett, K. B., Thompson, A., & Mills, K. I. (2017). Integrated analysis of the molecular action of Vorinostat identifies epi-sensitised targets for combination therapy. Oncotarget, 8(40), https://doi.org/10.18632/oncotarget.18910

Several histone deacetylase inhibitors including Vorinostat have received FDA approval for the treatment of haematological malignancies. However, data from these trials indicate that Vorinostat has limited efficacy as a monotherapy, prompting the nee... Read More about Integrated analysis of the molecular action of Vorinostat identifies epi-sensitised targets for combination therapy.

Decitabine-Vorinostat combination treatment in acute myeloid leukemia activates pathways with potential for novel triple therapy (2017)
Journal Article
Young, C. S., Clarke, K. M., Kettyle, L. M., Thompson, A., & Mills, K. I. (2017). Decitabine-Vorinostat combination treatment in acute myeloid leukemia activates pathways with potential for novel triple therapy. Oncotarget, 8(31), https://doi.org/10.18632/oncotarget.18009

Despite advancements in cancer therapeutics, acute myeloid leukemia patients over 60 years old have a 5-year survival rate of less than 8%. In an attempt to improve this, epigenetic modifying agents have been combined as therapies in clinical studies... Read More about Decitabine-Vorinostat combination treatment in acute myeloid leukemia activates pathways with potential for novel triple therapy.